Immunotherapy has led to a paradigm shift in the treatment of some malignancies, providing
long-term, durable responses for patients with advanced cancers. However, such therapy …

Background Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of
many cancers. However, the limited population that benefits from ICI therapy makes it …

Molecularly targeted therapy and immunotherapy have dramatically changed the landscape
of available treatment options for patients with advanced cancer. Improved understanding of …

Immunotherapy has emerged as a promising anti-cancer treatment, however, little is known
about the genetic characteristics that dictate response to immunotherapy. We develop a …

Despite decades of clinical and preclinical studies, the markers and mechanisms of
resistance to cancer immunotherapy, particularly immune checkpoint blockade (ICB), remain …

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …

Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

Summary The Cancer Genome Atlas revealed the genomic landscapes of human cancers.
In parallel, immunotherapy is transforming the treatment of advanced cancers. Unfortunately …

The immune response against cancer is orchestrated by various parameters and site-
dependent specificities have been poorly investigated. In our analyses of ten different …

Recent clinical successes with immunotherapy have resulted in expanding indications for
cancer therapy. To enhance antitumor immune responses, and to better choose specific …